MarketInOut Stock Screener Log In | Sign Up
 

Context Therapeutics Inc

NASDAQ • Healthcare • Biotechnology • Quote as of 05/08/2026
Context Therapeutics Inc stock price and volume chart

Company Profile

IndustryBiotechnology
SectorHealthcare
ExchangeNASDAQ
Market Capitalization215 mln
Float42.72 mln
Earnings Date08/12/2026

Piotroski F-Score

3 / 9
Below average

1-Year Forecast

6.00
Transformational upside

Relative Strength

78 / 100
Strongly outperforming

Debt / Equity

0.00
Debt-free

ROE

-44.88
Deeply negative

Dividend Yield

0.00%
No dividend

Business Description

Context Therapeutics is a Philadelphia-based drug development company focused on finding new ways to treat solid tumor cancers. Its main drug candidate, CTIM-76, is designed to harness the body's own immune cells to seek out and destroy cancer cells that carry a specific protein called Claudin 6. The company works alongside Integral Molecular to advance this approach through a shared licensing and development agreement.

Key Fundamentals

EPS-0.42
ROE-44.88
ROIC-2,349
ROA-42.40
EBITDA, mln-39.69
EV / EBITDA-3.71
EV / EBIT-3.71

Financial Strength

Piotroski F-Score 3 / 9
1-Year Target Price6.00
Short Ratio1.14
Short % of Float1.08

Price Performance & Relative Strength

Period Price Performance Relative Strength
1 Week 4.85% 81 / 100   
1 Month -8.11% 13 / 100   
2 Months -8.81% 25 / 100   
6 Months 111% 97 / 100   
1 Year 208% 95 / 100   



Disclaimer - Privacy Policy - Terms Of Service - Cookie Use Policy - FAQ - Contact Us